{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:40:48Z","timestamp":1790023248217,"version":"4.0.1"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010783","name":"Slovensk\u00e1 Akad\u00e9mia Vied","doi-asserted-by":"publisher","award":["313021T081"],"award-info":[{"award-number":["313021T081"]}],"id":[{"id":"10.13039\/100010783","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006109","name":"Vedeck\u00e1 Grantov\u00e1 Agent\u00fara M\u0160VVa\u0160 SR a SAV","doi-asserted-by":"publisher","award":["VEGA 2\/0088\/23"],"award-info":[{"award-number":["VEGA 2\/0088\/23"]}],"id":[{"id":"10.13039\/501100006109","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006109","name":"Vedeck\u00e1 Grantov\u00e1 Agent\u00fara M\u0160VVa\u0160 SR a SAV","doi-asserted-by":"publisher","award":["2\/0087\/23"],"award-info":[{"award-number":["2\/0087\/23"]}],"id":[{"id":"10.13039\/501100006109","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005357","name":"Slovak Research and Development Agency","doi-asserted-by":"publisher","award":["APVV-19-0212"],"award-info":[{"award-number":["APVV-19-0212"]}],"id":[{"id":"10.13039\/501100005357","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005357","name":"Slovak Research and Development Agency","doi-asserted-by":"publisher","award":["APVV-21-0215"],"award-info":[{"award-number":["APVV-21-0215"]}],"id":[{"id":"10.13039\/501100005357","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005357","name":"Slovak Research and Development Agency","doi-asserted-by":"publisher","award":["APVV-16-0484"],"award-info":[{"award-number":["APVV-16-0484"]}],"id":[{"id":"10.13039\/501100005357","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005357","name":"Slovak Research and Development Agency","doi-asserted-by":"publisher","award":["APVV-20-0183"],"award-info":[{"award-number":["APVV-20-0183"]}],"id":[{"id":"10.13039\/501100005357","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.nano.2024.102777","type":"journal-article","created":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T20:23:59Z","timestamp":1722889439000},"page":"102777","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Exploring the anti-myeloma potential of composite nanoparticles As4S4\/Fe3O4: Insights from in vitro, ex vivo and in vivo studies"],"prefix":"10.1016","volume":"62","author":[{"given":"Danka","family":"Cholujova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zdenka Lukacova","family":"Bujnakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Dutkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzana","family":"Valuskova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikoleta","family":"Csicsatkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Suroviakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Elisabeth","family":"Marinkovicova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Zbellova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenka","family":"Koklesova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Sedlak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teru","family":"Hideshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Jakubikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nano.2024.102777_bb0005","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.hoc.2023.12.010","article-title":"Molecular pathogenesis of multiple myeloma: clinical implications","volume":"38","author":"Maura","year":"2024","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.nano.2024.102777_bb0010","doi-asserted-by":"crossref","DOI":"10.1038\/s41417-024-00750-2","article-title":"CAR T therapies in multiple myeloma: unleashing the future","author":"Sheykhhasan","year":"2024","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.nano.2024.102777_bb0015","doi-asserted-by":"crossref","first-page":"1346211","DOI":"10.3389\/fimmu.2024.1346211","article-title":"Different evasion strategies in multiple myeloma","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.nano.2024.102777_bb0020","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15122674","article-title":"Optimized liposomal delivery of bortezomib for advancing treatment of multiple myeloma","volume":"15","author":"Zhang","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.nano.2024.102777_bb0025","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.actbio.2018.09.022","article-title":"Hyaluronic acid shell and disulfide-crosslinked core micelles for in vivo targeted delivery of bortezomib for the treatment of multiple myeloma","volume":"80","author":"Gu","year":"2018","journal-title":"Acta Biomater"},{"key":"10.1016\/j.nano.2024.102777_bb0030","doi-asserted-by":"crossref","first-page":"939","DOI":"10.2169\/internalmedicine.9567-17","article-title":"A phase I\/II study for dose-finding, and to investigate the safety, pharmacokinetics and preliminary efficacy of NK012, an SN-38-incorporating macromolecular polymeric micelle, in patients with multiple myeloma","volume":"57","author":"Ri","year":"2018","journal-title":"Intern Med"},{"key":"10.1016\/j.nano.2024.102777_bb0035","doi-asserted-by":"crossref","first-page":"20068","DOI":"10.1039\/C8RA01417E","article-title":"Preparation and characterization of erythrocyte membrane cloaked PLGA\/arsenic trioxide nanoparticles and evaluation of their in vitro anti-tumor effect","volume":"8","author":"Su","year":"2018","journal-title":"RSC Adv"},{"key":"10.1016\/j.nano.2024.102777_bb0040","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.msec.2016.11.122","article-title":"Polypropyleneimine and polyamidoamine dendrimer mediated enhanced solubilization of bortezomib: comparison and evaluation of mechanistic aspects by thermodynamics and molecular simulations","volume":"72","author":"Chaudhary","year":"2017","journal-title":"Mater Sci Eng C Mater Biol Appl"},{"key":"10.1016\/j.nano.2024.102777_bb0045","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1039\/D0TB02926B","article-title":"An oligopeptide\/aptamer-conjugated dendrimer-based nanocarrier for dual-targeting delivery to bone","volume":"9","author":"Ren","year":"2021","journal-title":"J Mater Chem B"},{"key":"10.1016\/j.nano.2024.102777_bb0050","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s11671-022-03707-2","article-title":"PEG@ carbon nanotubes composite as an effective nanocarrier of ixazomib for myeloma cancer therapy","volume":"17","author":"Elgamal","year":"2022","journal-title":"Nanoscale Res Lett"},{"key":"10.1016\/j.nano.2024.102777_bb0055","doi-asserted-by":"crossref","DOI":"10.3791\/58598","article-title":"Repression of multiple myeloma cell growth in vivo by single-wall carbon nanotube (SWCNT)-delivered MALAT1 antisense oligos","author":"Lin","year":"2018","journal-title":"J Vis Exp"},{"key":"10.1016\/j.nano.2024.102777_bb0060","doi-asserted-by":"crossref","first-page":"6312","DOI":"10.1021\/acsami.2c17214","article-title":"Targeted lymphoma therapy using a gold nanoframework-based drug delivery system","volume":"15","author":"Bariana","year":"2023","journal-title":"ACS Appl Mater Interfaces"},{"key":"10.1016\/j.nano.2024.102777_bb0065","doi-asserted-by":"crossref","first-page":"17961","DOI":"10.1038\/s41598-022-22672-5","article-title":"In vitro and ex vivo anti-myeloma effects of nanocomposite As(4)S(4)\/ZnS\/Fe(3)O(4)","volume":"12","author":"Cholujova","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.nano.2024.102777_bb0070","doi-asserted-by":"crossref","first-page":"109712","DOI":"10.1016\/j.biopha.2019.109712","article-title":"Zinc oxide nanoparticles induce human multiple myeloma cell death via reactive oxygen species and Cyt-C\/Apaf-1\/Caspase-9\/Caspase-3 signaling pathway in vitro","volume":"122","author":"Li","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.nano.2024.102777_bb0075","doi-asserted-by":"crossref","first-page":"40","DOI":"10.31083\/j.fbl2702040","article-title":"Noble metal nanomaterials for the diagnosis and treatment of hematological malignancies","volume":"27","author":"Huang","year":"2022","journal-title":"Front Biosci (Landmark Ed)"},{"key":"10.1016\/j.nano.2024.102777_bb0080","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.1021\/acsnano.9b09618","article-title":"Osteotropic radiolabeled nanophotosensitizer for imaging and treating multiple myeloma","volume":"14","author":"Tang","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.nano.2024.102777_bb0085","doi-asserted-by":"crossref","first-page":"1223695","DOI":"10.3389\/fimmu.2023.1223695","article-title":"Human T cells loaded with superparamagnetic iron oxide nanoparticles retain antigen-specific TCR functionality","volume":"14","author":"Pfister","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.nano.2024.102777_bb0090","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2217\/nnm.12.216","article-title":"Anti-ABCG2 monoclonal antibody in combination with paclitaxel nanoparticles against cancer stem-like cell activity in multiple myeloma","volume":"9","author":"Yang","year":"2014","journal-title":"Nanomedicine (Lond)"},{"key":"10.1016\/j.nano.2024.102777_bb0095","doi-asserted-by":"crossref","first-page":"e58491","DOI":"10.1371\/journal.pone.0058491","article-title":"Nano-encapsulation of arsenic trioxide enhances efficacy against murine lymphoma model while minimizing its impact on ovarian reserve in vitro and in vivo","volume":"8","author":"Ahn","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.nano.2024.102777_bb0100","doi-asserted-by":"crossref","first-page":"10845","DOI":"10.1002\/anie.201701366","article-title":"Smart human-serum-albumin-As(2) O(3) nanodrug with self-amplified folate receptor-targeting ability for chronic myeloid leukemia treatment","volume":"56","author":"Peng","year":"2017","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.nano.2024.102777_bb0105","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ejps.2006.05.002","article-title":"Evaluation of the in vitro activity and in vivo bioavailability of realgar nanoparticles prepared by cryo-grinding","volume":"29","author":"Wu","year":"2006","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.nano.2024.102777_bb0110","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/bjh.14974","article-title":"Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma","volume":"179","author":"Cholujova","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.nano.2024.102777_bb0115","doi-asserted-by":"crossref","first-page":"110683","DOI":"10.1016\/j.msec.2020.110683","article-title":"Preparation of As(4)S(4)\/Fe(3)O(4) nanosuspensions and in-vitro verification of their anticancer activity","volume":"110","author":"Bujnakova","year":"2020","journal-title":"Mater Sci Eng C Mater Biol Appl"},{"key":"10.1016\/j.nano.2024.102777_bb0120","doi-asserted-by":"crossref","first-page":"4409","DOI":"10.1182\/blood-2010-02-267344","article-title":"Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications","volume":"117","author":"Jakubikova","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.nano.2024.102777_bb0125","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrc.2016.108","article-title":"Cancer nanomedicine: progress, challenges and opportunities","volume":"17","author":"Shi","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.nano.2024.102777_bb0130","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/cgt.2017.16","article-title":"New methods in the diagnosis of cancer and gene therapy of cancer based on nanoparticles","volume":"24","author":"Zaimy","year":"2017","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.nano.2024.102777_bb0135","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1158\/1535-7163.MCT-15-0867","article-title":"Dual carfilzomib and doxorubicin-loaded liposomal nanoparticles for synergistic efficacy in multiple myeloma","volume":"15","author":"Ashley","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.nano.2024.102777_bb0140","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1158\/1078-0432.CCR-18-1909","article-title":"A phase I\/II trial of carfilzomib, pegylated liposomal doxorubicin, and dexamethasone for the treatment of relapsed\/refractory multiple myeloma","volume":"25","author":"Schroeder","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nano.2024.102777_bb0145","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13045-021-01096-0","article-title":"Nanomaterials for cancer therapy: current progress and perspectives","volume":"14","author":"Cheng","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.nano.2024.102777_bb0150","first-page":"1973","article-title":"The application of nanoparticles in cancer immunotherapy: targeting tumor microenvironment","volume":"6","author":"Yang","year":"2021","journal-title":"Bioact Mater"},{"key":"10.1016\/j.nano.2024.102777_bb0155","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1200\/JCO.2006.10.5460","article-title":"Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression","volume":"25","author":"Orlowski","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nano.2024.102777_bb0160","doi-asserted-by":"crossref","first-page":"8314176","DOI":"10.1155\/2022\/8314176","article-title":"Oral realgar-indigo naturalis formula treatment for acute promyelocytic leukemia in children: a randomized, control clinical trial","volume":"2022","author":"Luo","year":"2022","journal-title":"Evid Based Complement Alternat Med"},{"key":"10.1016\/j.nano.2024.102777_bb0165","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S1470-2045(18)30295-X","article-title":"Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.nano.2024.102777_bb0170","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jconrel.2021.08.035","article-title":"Imatinib co-loaded targeted realgar nanocrystal for synergistic therapy of chronic myeloid leukemia","volume":"338","author":"Wang","year":"2021","journal-title":"J Control Release"},{"key":"10.1016\/j.nano.2024.102777_bb0175","article-title":"Drug-loaded biocompatible nanocarriers embedded in Poloxamer 407 hydrogels as therapeutic formulations","volume":"6","author":"Giuliano","year":"2018","journal-title":"Medicines (Basel)"},{"key":"10.1016\/j.nano.2024.102777_bb0180","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1166\/jbn.2014.1730","article-title":"Gamma-Fe2O3 nanoparticles increase therapeutic efficacy of combination with paclitaxel and anti-ABCG2 monoclonal antibody on multiple myeloma cancer stem cells in mouse model","volume":"10","author":"Yang","year":"2014","journal-title":"J Biomed Nanotechnol"},{"key":"10.1016\/j.nano.2024.102777_bb0185","first-page":"3275","article-title":"Inducing cell cycle arrest and apoptosis by dimercaptosuccinic acid modified Fe3O4 magnetic nanoparticles combined with nontoxic concentration of bortezomib and gambogic acid in RPMI-8226 cells","volume":"10","author":"Zhang","year":"2015","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.nano.2024.102777_bb0190","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1038\/oncsis.2015.35","article-title":"Targeting self-renewal pathways in cancer stem cells: clinical implications for cancer therapy","volume":"4","author":"Borah","year":"2015","journal-title":"Oncogenesis"},{"key":"10.1016\/j.nano.2024.102777_bb0195","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/bjh.12563","article-title":"Myeloma stem cell concepts, heterogeneity and plasticity of multiple myeloma","volume":"163","author":"Hajek","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.nano.2024.102777_bb0200","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1182\/blood-2012-06-436220","article-title":"Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma","volume":"121","author":"Chaidos","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.nano.2024.102777_bb0205","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1172\/JCI61188","article-title":"Molecular pathogenesis of multiple myeloma and its premalignant precursor","volume":"122","author":"Kuehl","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.nano.2024.102777_bb0210","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.canlet.2009.11.005","article-title":"Arsenic trioxide-mediated Notch pathway inhibition depletes the cancer stem-like cell population in gliomas","volume":"292","author":"Zhen","year":"2010","journal-title":"Cancer Lett"},{"key":"10.1016\/j.nano.2024.102777_bb0215","doi-asserted-by":"crossref","first-page":"13432","DOI":"10.1073\/pnas.1006822107","article-title":"Arsenic antagonizes the hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector","volume":"107","author":"Kim","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nano.2024.102777_bb0220","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1196\/annals.1378.022","article-title":"Arsenic trioxide represses NF-kappaB activation and increases apoptosis in ATRA-treated APL cells","volume":"1090","author":"Mathieu","year":"2006","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.nano.2024.102777_bb0225","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/nm.1891","article-title":"Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation","volume":"14","author":"Nasr","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.nano.2024.102777_bb0230","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1080\/10717544.2019.1672830","article-title":"(\u2212)-Epigallocatechin-3-gallate encapsulated realgar nanoparticles exhibit enhanced anticancer therapeutic efficacy against acute promyelocytic leukemia","volume":"26","author":"Fang","year":"2019","journal-title":"Drug Deliv"}],"container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963424000467?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963424000467?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:32:59Z","timestamp":1778617979000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1549963424000467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":46,"alternative-id":["S1549963424000467"],"URL":"https:\/\/doi.org\/10.1016\/j.nano.2024.102777","relation":{},"ISSN":["1549-9634"],"issn-type":[{"value":"1549-9634","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring the anti-myeloma potential of composite nanoparticles As4S4\/Fe3O4: Insights from in vitro, ex vivo and in vivo studies","name":"articletitle","label":"Article Title"},{"value":"Nanomedicine: Nanotechnology, Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nano.2024.102777","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102777"}}